Management Team

Ophthotech has assembled a team with proven experience in research, clinical development and commercialization of novel therapies for diseases of the eye.

Glenn Sblendorio

Glenn P. Sblendorio, M.B.A.

President and Chief Executive Officer

Glenn Sblendorio, M.B.A., is President and Chief Executive Officer of Ophthotech Corporation. He joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. Mr. Sblendorio also served as a member of the Board of Directors of Ophthotech from 2013 to 2016. Prior to joining Ophthotech, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BBA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.
Evelyn Harrison

Evelyn Harrison, M.B.A.

Chief Clinical Operations Officer

Evelyn Harrison, M.B.A., is the Chief Clinical Operations Officer of Ophthotech Corporation. She brings more than 23 years of management and clinical research experience.

Prior to joining Ophthotech, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. During her stint at this company, she played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.

Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.

Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.

Ms. Harrison holds a B.A. degree in Biology from Hofstra University and a Master of Business Administration (M.B.A.) degree from Manhattan College.

David J. Carroll

David F. Carroll, M.B.A.

Chief Financial Officer

David Carroll, M.B.A, is the Chief Financial Officer of Ophthotech Corporation. joined Ophthotech in 2016 and has more than 25 years of experience in the life sciences industry. Prior to joining the Company, Mr. Carroll spent eight years at The Medicines Company in several senior financial leadership roles, including Vice President, Controller and most recently, Senior Vice President, Chief Accounting Officer. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Novartis, and Bristol-Myers Squibb.

Mr. Carroll is a certified public accountant and received a BA from Ursinus College magna cum laude and an MBA from Rutgers University.

Kourous A. Rezaei, M.D.

Kourous A. Rezaei, M.D.

Senior Vice President, Medical Strategy

Dr. Rezaei serves as the Senior Vice President, Medical Strategy of Ophthotech Corporation. He is a board certified ophthalmologist that specializes in the medical and surgical treatment of vitreoretinal diseases, and has been recognized with multiple awards in the ophthalmology space, including the Beem Fisher Award from the Chicago Ophthalmological Society and the American Academy of Ophthalmology Achievement Award. Dr. Rezaei had served on the Editorial Board of the journal of Investigative Ophthalmology & Visual Science (IOVS) and currently is a voting member on the Board of Directors of the American Society of Retina Specialists (ASRS). He has authored over 30 articles, five medical textbook chapters, and has presented over 80 abstracts in 26 countries. Dr. Rezaei is an Associate Professor of Ophthalmology and the Director of the Vitreoretinal Fellowship Program at Rush University Medical Center and is a senior partner at Illinois Retina Associates in Chicago. Previously, he was the Director of Vitreoretinal Service at the University of Chicago. Dr. Rezaei also founded “ChannelR”, a digital media education program for retina specialists.

Dr. Rezaei received his medical degree from the University of Cologne in Germany. He served as chief resident while completing his residency at the University of Chicago. Dr. Rezaei completed his vitreoretinal surgery fellowship at the Kresge Eye Institute in Detroit.

Dr. Thomas A. Ciulla, M.D., M.B.A.

Thomas A. Ciulla, M.D., M.B.A.

Vice President, Clinical Strategy

Thomas Ciulla, M.D., M.B.A. is Vice President, Clinical Strategy of Ophthotech Corporation. Dr. Ciulla graduated from Harvard College and the University of California San Francisco UCSF Medical School, followed by internship and residency at Harvard Medical School, and then fellowship at Tufts Medical School. A board-certified ophthalmologist and retina specialist, he co-directed the retina service and ocular angiogenesis research laboratory at Indiana University School of Medicine, one of the largest U.S. medical schools, and remains a volunteer Clinical Professor of Ophthalmology. He served on the board of directors of one of the largest multi-subspecialty ophthalmology institutes in the Midwest. He was principal investigator, medical monitor, and member of scientific advisory, data safety monitoring or writing committees in over 100 national clinical trials, including CATT and registration trials for nearly all FDA-approved retinal therapeutics. He served on journal editorial boards, edited several textbooks, presented in over 100 conferences, and co-authored over 100 Medline-indexed papers, including the first published US-based randomized clinical trial on any intravitreal therapy in neovascular AMD. He is an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, American Society of Retina Specialists, and American Academy of Ophthalmology, with senior honor and achievement awards from the latter two societies. Prior to entering industry, he earned an MBA from Indiana University’s Kelley School of Business, specializing in the business of medicine.
Dan Salain

Dan Salain

Senior Vice President, Technical Operations

Mr. Salain brings over 25 years of global pharmaceutical experience in Manufacturing, Supply Chain, Strategic Sourcing, Distribution, Quality, Operations and Business Development. Over the past 25 years Dan has participated in the successful launch and introduction of over 30 products globally including Zenpep, Lamictal, Amrix, Canasa, and Metadate CD. Most recently Dan was Vice President, Global Supply Chain and Manufacturing at Aptalis Pharma where he built a supply chain team and managed manufacturing sites in Italy, France, Canada and the US. Prior to joining Aptalis Dan was the Vice President of Operations at Eurand where he lead several technology and licensing deals in addition to running the Operations team. He earned a Bachelor of Science degree in chemistry from the University of Indianapolis.
Keith Westby

Keith Westby, M.B.A.

Senior Vice President and Chief Operating Officer

Keith Westby is Senior Vice President and Chief Operating Officer of Ophthotech Corporation. Westby joined Ophthotech in 2007 and has more than fifteen years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations of Ophthotech. Prior to joining Ophthotech, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen® (a pegylated oligonucleotide). Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a Bachelor of Science degree in Applied Physics from the State University of New York, College at Geneseo, a Master of Science degree in Engineering Management from Drexel University, and a Master of Business Administration degree from Columbia Business School.
Barbara_Wood

Barbara Wood

Senior Vice President and General Counsel

Barbara Wood is Senior Vice President and General Counsel of Ophthotech Corporation. Ms. Wood has been practicing law for more than 25 years. Prior to joining Ophthotech, she was Senior Vice President and General Counsel at OSI Pharmaceuticals, Inc., where she played a significant role in the integration and transition process when Astellas Pharma acquired OSI in 2010.

Before joining OSI, Ms. Wood was a partner at the New York firm of Squadron, Ellenoff, Plesent & Sheinfeld (now part of Hogan Lovells), focusing on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters. While at Squadron Ellenoff, she also worked on transactions for some of the earliest biotech companies, representing an early biotech venture capitalist and angel investor. Ms. Wood received her law degree from Columbia Law School and has a Bachelor of Arts (B.A.) degree in Economics and Classics from Connecticut College.